PLATBIO

Developing  new  drug  using  a  novel  drug discovery  platform

with  sustainable  growth  strategy

 

OUR MISSION

1. Our mission is to lead novel drug development program by innovative and revolutionary platform.

2. We dedicate ourselves to establishment of straightforward translational R&D strategy for non-clinical and clinical program

3. With our proprietary translational research capability and new drug screening platforms, we innovate the new drug development and lead in overcoming the illness. 

 Established in October, 2018

Developing  new  drug  using

a  novel  drug  discovery  platform

with  sustainable  growth  strategy

CHAIRMAN

Scientific Founder

Sun Jin Kim 

M.D., Ph.D

Former / Executive Vice President, CMO, Executive Director of Research Center, Hanmi Pharmaceutical Co., Ltd 

Former / Professor, Cancer Biology, Clinical Translational & Metastasis Research Center, The University of Texas, MD Anderson Cancer Center

Former / Invited Scientist of National Cancer Center Research Institute, Tokyo, Japan

Postgraduate School, Seoul National University

 

College  of Medicine, Seoul National University

 

College of Natural Science, Seoul National University

GLOBAL LEADER

HONORS AND AWARDS

[Scholar in Training Award] 

American Association for Cancer Research l 2002

[Bristol-Myers Squibb Award in Clinical Translation Research] 

Bristol-Myers Squibb l 2002

[Scholar in Training Award] 

American Association for Cancer Research l 2001

[Bristol-Myers Squibb Award in Clinical Translation Research] 

Bristol-Myers Squibb l 2001

[The Best Achievement of the Year] 

Korean Urologic Cancer Association l 1998

CHIEF INSTRUCTOR

NCI-sponsored orthotopic animal model training program

 

Our PLAtform

ORTHOTOPIC ANIMAL MODELS

Platform for Revolutionary Identification & Isolation

of Novel Targets

ORTHOTOPIC ANIMAL MODEL

TUMOR ‘TARGET’

The growth and spread of a tumor involves the cancer cells themselves as well as the environment around them. Crosstalk of tumor and organ microenvironment should be considered for the establishment of right tumor models for the pre-clinical research and evaluation of anti-cancer drugs. Orthotopic tumor models are powerful tools for mimicking the interaction between tumor and organ microenvironment. The organ-specific microenvironment induces tumor growth and specific signatures similar to that of the original tumor.

UNMET NEEDS

1. Limitation in target excavation from discrepancy between preclinical (laboratory) and clinical reality

 - Despite of efforts to hasten the process of drug development using innovative technologies, the current efforts still remain to be low in cost effectiveness. 

 

2. Tremendous increase in development cost

- Cost to develop new pharmaceutical drug now exceeds $2.5b

- A benchmark report estimates that the cost of bringing a drug to market has more than doubled in the past 10 years

 

3. Increase of difficulties in developmental process 

 - Complexed regimens: change of analogue concept to digital precision medicine

Proposed solution to overcome unmet needs with

 

New approach with genomics and proteomics driven platform

 

Platform for Revolutionary Identification & Isolation of Novel Targets,  PRIINT™

Cross-species hybridization of microarray experiment (CHME)

RNA

Custom antibody array with experimental sera from mice 

IHC analyses with experimental tissues from mice

Patients
tissues & sera

1. Establishment of precise orthotopic animal models

2. Revolutionary identification & isolation of novel targets with              tissues from orthotopic animal models by bioinformatics

3. Cross-validation of tumor targets in the experimental animal              tissues and human sera/surgical specimens

Confirmed list of novel targets in pancreatic and ovarian cancers;

Expansion to various solid tumors

Confirmed up-regulated protein encoding genes in cancers & application

Protein Characterization

Pathway/Interaction, Class, Localization, Function…

Approach

Monitoring Markers

Therapeutic

Targets

Screening Markers

Clinical

translational research

"As a systems person, I am a strong believer in using translational tools, including in vivo animal models to further increase positive predictivity. "

Discovering Novel Drug Targets is Complicated, and We all Know about their Low Success Rate in the Clinic. 

With Our Novel Drug Screening Platform, We Innovate the Process of Target Screening.

*Paul Mc... et al.
Biochemical  Pharmacology,87 (2014) 162–171.

 

CRO / Consultation

Evaluation of efficacy by

orthotopic animal models 

 

Leading drug repositioning 

 

Development of therapeutic regimensincluding combination therapies

CRO/Consultation for nonclinical and clinical development 

ORTHOTOPIC  /

METASTASIS ANIMAL MODEL

Brain
Model

Prostate
Model

Pancreas
Model

Ovary
Model

Ear
Model

Bone Metastasis
Model

Intra-cardiac
Model

Lung

Metastasis
Model

•Bone (Metastasis) Model

•Brain Model

•Breast (MFP) Model

•Bladder Model

•Colon Model

•Intra-cardiac (Heart) Model

•Kidney Model

•Liver (Metastasis) Model

•Lung (Metastasis) Model

•Ovary Model

•Pancreas Model

•Prostate Model

•AML (BMI) Model

STRATEGY

1. In House Discovery of Novel Drug
and Diagnostic Marker with
PRIINT

2. Open Assisted Innovation Via
in House Validation Technology

3. Contracted Translational Research
Business: Maximization of Value

 

Validation in Animal Models by Simulating Clinical Reality  

- Clinical Application

(Appropriate Model, Regimen, Unmet Needs, Differentiation) 

Join Us

We are always looking for talented people to join us.

Current Openings: Science & Administrative positions 

E-mail us at 

talent@platbio.com

 

Contact

Business

Development

Platbio Inc.

 

E: info@platbio.com

T: +82-31-8007-3332

F: +82-31-8007-3363

#1501, Ace GwanggyoTower 2, 91, 

Changnyong-daero256beon-gil, 

Yeongtong-gu, Suwon-si, Gyeonggi-do,

Republic of Korea 16229